Valuation dashboard for Fonar Corp. (FONR) with P/E 18.90, P/B 0.66, EV/EBITDA 6.47 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
FONAR Corporation, together with its subsidiaries, engages in the designing, manufacturing, selling, and servicing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases, abnormalities, other medical conditions, and injuries in the United States. It operates in two segments: Medical Equipment, and Physician Management and Diagnostic Services.
Analysis Summary
Fonar Corp. reported revenue of $104.4M in the most recent fiscal year, growing at a 5-year CAGR of 4.0%. Net income reached $8.3M, with a 0.2% 5-year CAGR.
Trailing-twelve-month margins: gross margin 40.3%, operating margin 9.0%, net margin 6.4%.
At the current price of $19.09, FONR trades at a P/E of 18.90 and an ROE of 3.81%. Market capitalisation stands at $118M.
Balance sheet quality for FONR: current ratio of 8.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 18.90 |
| Price / Book | 0.66 |
| EV / EBITDA | 6.47 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $25.81 |
| vs Current Price | +35.2% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| FONR | Fonar Corp. | $118M | 18.90 | 0.66 | 3.8% |
| 0J5Q.L | Hologic, Inc. | $16.9B | 31.08 | 3.24 | 11.1% |
| LLY | Eli Lilly and Company | $1.1T | 38.55 | 30.35 | 92.6% |
| JNJ | Johnson & Johnson | $650.6B | 31.40 | 7.80 | 32.9% |
| ABBV | AbbVie Inc. | $466.0B | 77.13 | -129.2% | |
| 0QCV.L | AbbVie Inc. | $397.1B | |||
| 0QAH.L | Merck & Co., Inc. | $367.4B | 117.56 | 8.73 | 6.6% |
| MRK | Merck & Co., Inc. | $362.5B | 117.30 | 8.71 | 6.6% |
Price
| Price | $19.09 |
| Market Cap | $118M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 3.81% |
| Return on Invested Capital | 3.59% |
| Return on Assets | 3.05% |
| Gross Margin | 40.26% |
| Operating Margin | 9.05% |
| Net Margin | 6.35% |
Related companies: APYX · ARTV · EDAP · HYPR · IFRX · LUNG · NSPR
Explore sector: Healthcare · Medical - Equipment & Services
More sections of FONR: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks